BJDX קפיטליזציה חשבונאית Bluejay Diagnostics, Inc.

Bluejay Diagnostics (BJDX) is developing the Symphony platform for the rapid diagnosis of severe pathologies, investing heavily in the creation of precise portable sensors. This daily price chart on the GURU.Markets platform reflects the asset's trend, whose efficiency is currently limited by engineering costs, while the 0.02 metric awaits an increase in orders. The business relies on robotic cartridges that replace laboratory staff with instantaneous blood analysis performed directly at the patient's side.

Investors determine an asset's margin of safety through the difference between the market price and the net asset value, excluding liabilities from total assets. For Bluejay Diagnostics (BJDX), the trend in book capitalization reflects the capitalization of the costly Symphony platform infrastructure, where the high cost of equipment and cartridges forms the fundamental basis of the business value, transforming the company into a defensive technological asset.